Moderna 股价上涨，因为美国 FDA 同意审查其流感疫苗

Shares of vaccine maker Moderna (MRNA.O) up 3.1% at $45.33 premarket Co says the U.S. FDA accepted its application to review mRNA-1010, a vaccine targeting seasonal influenza using messenger RNA technology The FDA had initially refused to review the vaccine, citing flaws in the trial design MRNA says it has sought full approval for the vaccine for ages 50 to 64 years and a faster, conditional approval for those above 65 years of age with “a post-marketing requirement to conduct an additional study in older adults” Also adds that the vaccine, if approved, could be made available as early as the ²⁰²⁶⁄₂₇ flu season  mRNA-1010 is also being reviewed in Europe, Canada and Australia Shares fell ~29% in 2025